Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q27853086)
Watch
English
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
scientific article
Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion-Positive Cancer
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
PubMed
PubMed ID
25351743
retrieved
13 November 2016
title
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer
(English)
1 reference
stated in
PubMed
PubMed ID
25351743
retrieved
13 November 2016
main subject
crizotinib
1 reference
based on heuristic
inferred from title
author
Ryohei Katayama
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Luc Friboulet
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
author name string
Yuka Kobayashi
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Elizabeth L Lockerman
series ordinal
4
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Sumie Koike
series ordinal
5
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Alice T Shaw
series ordinal
6
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Jeffrey A Engelman
series ordinal
7
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Naoya Fujita
series ordinal
8
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
language of work or name
English
0 references
publication date
1 January 2015
0 references
published in
Clinical Cancer Research
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
volume
21
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
issue
1
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
page(s)
166-174
1 reference
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
cites work
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Ceritinib in ALK-rearranged non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
ROS1 rearrangements define a unique molecular class of lung cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
MEK1 mutations confer resistance to MEK and B-RAF inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
The protein kinase complement of the human genome
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
20 March 2017
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
29 September 2017
RET, ROS1 and ALK fusions in lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
29 September 2017
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
29 September 2017
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
29 September 2017
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
2 June 2018
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
27 November 2018
Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
27 November 2018
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
27 November 2018
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4286456
retrieved
27 November 2018
Identifiers
DOI
10.1158/1078-0432.CCR-14-1385
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560063
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
OpenCitations bibliographic resource ID
560063
1 reference
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560063
PMCID
4286456
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560063
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
PubMed ID
25351743
2 references
stated in
Consolidated OpenCitations Corpus – April 2017
OpenCitations bibliographic resource ID
560063
stated in
Europe PubMed Central
PMCID
4286456
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25351743%20AND%20SRC:MED&resulttype=core&format=json
retrieved
7 June 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
